

# Fabienne Marcellin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1846404/publications.pdf>

Version: 2024-02-01

108  
papers

1,615  
citations

304743

22  
h-index

377865

34  
g-index

109  
all docs

109  
docs citations

109  
times ranked

2130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mindfulness as a Protective Factor Against Increased Tobacco and Alcohol Use in Hospital Workers Following the First COVID-19-Related Lockdown: a Study in Southern France. <i>International Journal of Mental Health and Addiction</i> , 2023, 21, 2583-2603.	7.4	3
2	Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 5-11.	2.9	2
3	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 38-49.	3.9	5
4	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 677-689.	2.9	6
5	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , 2022, 42, 249-252.	3.9	3
6	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). <i>Clinical Nutrition</i> , 2022, 41, 610-619.	5.0	8
7	Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS) Tj ETQq1 1 0.784314 rgBT /Overlo	5.1	8
8	Use of psychoactive substances by night-shift hospital healthcare workers during the first wave of the COVID-19 pandemic: a cross-sectional study based in Parisian public hospitals (ALADDIN). <i>BMJ Open</i> , 2022, 12, e055699.	1.9	5
9	Knowledge of liver fibrosis stage among adults with <scp>NAFLD</scp>/<scp>NASH</scp> improves adherence to lifestyle changes. <i>Liver International</i> , 2022, 42, 984-994.	3.9	24
10	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. <i>JHEP Reports</i> , 2022, 4, 100481.	4.9	3
11	HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH) Tj ETQq1,1 0.784314 rgBT /	1.7	1
12	Tobacco use in people living with HIV: The need for complementary descriptive data to see beyond the smoke screen. <i>International Journal of Drug Policy</i> , 2022, 102, 103616.	3.3	1
13	Social and professional recognition are key determinants of quality of life at work among night-shift healthcare workers in Paris public hospitals (AP-HP ALADDIN COVID-19 survey). <i>PLoS ONE</i> , 2022, 17, e0265724.	2.5	10
14	Examining the Relationships between Mindfulness and Tobacco Craving Factors. <i>Substance Use and Misuse</i> , 2022, 57, 656-659.	1.4	2
15	Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey). <i>Hepatology Communications</i> , 2022, 6, 1005-1015.	4.3	7
16	Impact of the <scp>COVID</scp> â€19 crisis on healthcare workers: The need to address quality of working life issues. <i>Respirology</i> , 2022, 27, 469-471.	2.3	1
17	Stigma and care avoidance in people with unhealthy alcohol use: A call for research and action. <i>Journal of Hepatology</i> , 2022, 77, 1221-1222.	3.7	4
18	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	1

#	ARTICLE	IF	CITATIONS
19	Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. <i>Liver International</i> , 2021, 41, 2328-2340.	3.9	3
20	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1147-1156.	4.4	6
21	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>AIDS and Behavior</i> , 2021, 25, 4141-4153.	2.7	8
22	Hepatitis B Vaccination in Senegalese Children: Coverage, Timeliness, and Sociodemographic Determinants of Non-Adherence to Immunisation Schedules (ANRS 12356 AmBASS Survey). <i>Vaccines</i> , 2021, 9, 510.	4.4	9
23	Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER). <i>Liver International</i> , 2021, 41, 1694-1698.	3.9	0
24	Sibling status, home birth, tattoos and stitches are risk factors for chronic hepatitis B virus infection in Senegalese children: A cross-sectional survey. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1515-1525.	2.0	4
25	Post-HCV cure self-reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1665-1667.	2.0	2
26	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <i>Journal of Clinical Virology</i> , 2021, 144, 104987.	3.1	2
27	Elevated Fatty Liver Index as a Risk Factor for All-cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>Hepatology</i> , 2020, 71, 1182-1197.	7.3	8
28	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). <i>Addiction</i> , 2020, 115, 573-582.	3.3	16
29	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). <i>AIDS and Behavior</i> , 2020, 24, 1069-1084.	2.7	12
30	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH). <i>Journal of Hepatology</i> , 2020, 72, 588-591.	3.7	7
31	Alcohol Use Patterns and Liver Outcomes: Is There Really a Difference Between Drinking Beer and Drinking Wine?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1650-1651.	4.4	0
32	Patient-reported outcomes to enhance person-centred HIV care. <i>Lancet HIV</i> , 2020, 7, e59-e68.	4.7	79
33	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS Tj ETQq1). <i>Journal of Hepatology</i> , 2020, 72, 1078-1084.	2.0	13
34	Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2020, 27, 1462-1472.	2.0	6
35	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). <i>Nutrients</i> , 2020, 12, 2532.	4.1	7
36	Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort. <i>Clinical Infectious Diseases</i> , 2020, 71, 2536-2538.	5.8	2

#	ARTICLE	IF	CITATIONS
37	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. <i>Aids</i> , 2020, 34, 953-954.	2.2	5
38	Letter to the Editor: Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use. <i>Hepatology</i> , 2019, 70, 443-444.	7.3	1
39	France removes hepatitis C treatment prescriber restrictions” But what is the impact of the delay for key populations?. <i>Liver International</i> , 2019, 39, 2418-2419.	3.9	4
40	Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers’ perspective using a mixed methods approach. <i>BMC Health Services Research</i> , 2019, 19, 627.	2.2	12
41	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <i>International Journal of Drug Policy</i> , 2019, 72, 61-68.	3.3	23
42	Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AMBASS ANRS 12356). <i>BMJ Open</i> , 2019, 9, e030211.	1.9	12
43	Sleep disturbances in HIV-HCV coinfecting patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort). <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1508-1517.	1.6	9
44	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2018, 68, 845-847.	3.7	9
45	Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). <i>HIV Medicine</i> , 2018, 19, 227-237.	2.2	10
46	Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance. <i>Journal of Viral Hepatitis</i> , 2018, 25, 314-315.	2.0	2
47	Access to care for people with alcohol use disorder in France: a mixed-method cross-sectional study protocol (ASIA). <i>BMJ Open</i> , 2018, 8, e024669.	1.9	1
48	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). <i>American Journal of Gastroenterology</i> , 2018, 113, 1729-1732.	0.4	1
49	Protective effect of cannabis and coffee consumption on HCV-related mortality in French HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort). <i>Journal of Hepatology</i> , 2018, 68, S142-S143.	3.7	5
50	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS CO-13 HEPAVIH Cohort). <i>Nutrients</i> , 2018, 10, 705.	4.1	18
51	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-infected patients (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , 2018, 25, 171-179.	2.0	23
52	No significant effect of cannabis use on the count and percentage of circulating CD4 T cells in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH French cohort). <i>Drug and Alcohol Review</i> , 2017, 36, 227-238.	2.1	18
53	Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 1-10.	3.0	36
54	Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVH cohort. <i>Addiction</i> , 2017, 112, 1669-1679.	3.3	10

#	ARTICLE	IF	CITATIONS
55	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	2.7	4
56	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2017, 67, 1157-1167.	3.7	25
57	Self-Reported Botherome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 110-119.	1.2	10
58	Disclosure of HIV Status Beyond Sexual Partners by People Living with HIV in France: A Call for Help? Results from the National Cross-Sectional Survey ANRS-VESPA2. <i>AIDS and Behavior</i> , 2017, 21, 196-206.	2.7	9
59	Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). <i>PLoS ONE</i> , 2017, 12, e0171645.	2.5	25
60	Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH). <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 786-791.	1.6	4
61	Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey. <i>Journal of the International AIDS Society</i> , 2016, 19, 20095.	3.0	13
62	From first-generation hepatitis C virus protease inhibitors to direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 733-734.	1.6	3
63	Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1003-1007.	1.6	7
64	Heterosexual practices of women and men living with HIV attending hospital outpatient services (ANRS-VESPA2 survey): a French comparative study with the general population (CSF survey). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1345-1354.	1.2	4
65	A reduced factor structure for the PROQOL-HIV questionnaire provided reliable indicators of health-related quality of life. <i>Journal of Clinical Epidemiology</i> , 2016, 72, 116-125.	5.0	10
66	Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French) <i>TJ ETQq0 0 0,rgBT /Overlock 10 Tf</i>		
67	Suicidal risk among patients enrolled in methadone maintenance treatment: HCV status and implications for suicide prevention (ANRS Methaville). <i>Comprehensive Psychiatry</i> , 2015, 62, 123-131.	3.1	12
68	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). <i>Clinical Infectious Diseases</i> , 2015, 61, 40-48.	5.8	21
69	Comparison of risk factors in HIV-infected men who have sex with men, coinfecting or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). <i>Sexually Transmitted Infections</i> , 2015, 91, 21-23.	1.9	21
70	Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 701-713.	3.0	4
71	Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, S29-S40.	1.2	28
72	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 351-358.	3.0	5

#	ARTICLE	IF	CITATIONS
73	High Levels of Alcohol Consumption Increase the Risk of Advanced Hepatic Fibrosis in HIV/Hepatitis C Virus-Coinfected Patients: A Sex-Based Analysis Using Transient Elastography at Enrollment in the HEPAVIH ANRS CO13 Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 1190-1192.	5.8	15
74	Predictors of non-prescribed opioid use after one year of methadone treatment: An attributable-risk approach (ANRS-Methaville trial). <i>Drug and Alcohol Dependence</i> , 2014, 135, 1-8.	3.2	32
75	Predictors of Non-adherence to Methadone Maintenance Treatment in Opioid-dependent Individuals: Implications for Clinicians. <i>Current Pharmaceutical Design</i> , 2014, 20, 4097-4105.	1.9	44
76	Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 239-250.	4.4	24
77	Self-reported alcohol abuse in HIV/HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVH ANRS CO13) <i>TJ ETQq1 3.0.784314rgBT /Ov</i>	3.0	14
78	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon – Data from the STRATALL ANRS 12110/ESTHER trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 347-355.	1.2	6
79	Susceptibility to Transmitting HIV in Patients Initiating Antiretroviral Therapy in Rural District Hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial). <i>PLoS ONE</i> , 2013, 8, e62611.	2.5	7
80	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon -- data from the STRATALL ANRS 12110/ESTHER trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2013, 25, 347-55.	1.2	5
81	Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon. <i>Health Policy and Planning</i> , 2012, 27, 301-315.	2.7	34
82	Choice of therapeutic strategies in the context of HIV infection: key role of patient-reported outcomes. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 403-406.	4.4	6
83	Adherence as a Predictor of Sexual Behaviors in People Living with HIV/AIDS during the First Year of Antiretroviral Therapy in Rural Cameroon: Data from Stratall ANRS 12110/ESTHER Trial. <i>PLoS ONE</i> , 2012, 7, e36118.	2.5	9
84	Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. <i>Social Science and Medicine</i> , 2011, 72, 1383-1392.	3.8	100
85	Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care. <i>Antiviral Therapy</i> , 2011, 16, 423-428.	1.0	2
86	Individual and Structural Factors Associated With HIV Status Disclosure to Main Partner in Cameroon: ANRS 12-116 EVAL Survey, 2006–2007. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, S22-S26.	2.1	13
87	Adherence to Antiretroviral Treatment in HIV-Positive Patients in the Cameroon Context: Promoting the Use of Medication Reminder Methods. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, S40-S43.	2.1	30
88	Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 501-507.	1.2	4
89	Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12–116). <i>Aids</i> , 2010, 24, S17-S25.	2.2	22
90	Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). <i>Tropical Medicine and International Health</i> , 2010, 15, 706-712.	2.3	14

#	ARTICLE	IF	CITATIONS
91	Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey). <i>Sexually Transmitted Infections</i> , 2010, 86, 148-154.	1.9	27
92	Desire for a child among HIV-infected women receiving antiretroviral therapy in Cameroon: results from the national survey EVAL (ANRS 12-116). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 441-451.	1.2	15
93	Delayed first consultation after diagnosis of HIV infection in Cameroon. <i>Aids</i> , 2009, 23, 1015-1019.	2.2	18
94	Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. <i>Bulletin of the World Health Organization</i> , 2009, 87, 279-287.	3.3	59
95	Effect of Anxiety Symptoms on Adherence to Highly Active Antiretroviral Therapy in HIV-Infected Women. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1328-1329.	2.2	6
96	Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). <i>Tropical Medicine and International Health</i> , 2008, 13, 1470-1478.	2.3	58
97	Buprenorphine sniffing as a response to inadequate care in substituted patients: Results from the Subazur survey in south-eastern France. <i>Addictive Behaviors</i> , 2008, 33, 1625-1629.	3.0	33
98	Depressive Symptoms and Exposure to Efavirenz in West African HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2008, 9, 445-447.	2.0	8
99	Impaired Anger Control as an Underappreciated Side Effect of Treatments for Chronic HCV Infection in HIV-HCV Coinfected Patients. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 92-96.	2.2	18
100	Effect of Lopinavir/Ritonavir Monotherapy on Quality of Life and Self-Reported Symptoms among Antiretroviral-Naive Patients: Results of the MONARK Trial. <i>Antiviral Therapy</i> , 2008, 13, 591-599.	1.0	11
101	Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1105-1113.	1.1	50
102	Self-Reported Fatigue and Depressive Symptoms as Main Indicators of the Quality of Life (QOL) of Patients Living with HIV and Hepatitis C: Implications for Clinical Management and Future Research. <i>HIV Clinical Trials</i> , 2007, 8, 320-327.	2.0	68
103	Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study. <i>Aids</i> , 2007, 21, S19-S27.	2.2	74
104	Adding HCV Treatment to HIV Treatment in HIV-HCV Coinfected Patients: The Impact on the Different Dimensions of Fatigue and Self-Reported Side Effects. <i>Journal of Pain and Symptom Management</i> , 2007, 34, 413-421.	1.2	15
105	Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). <i>Quality of Life Research</i> , 2007, 16, 577-591.	3.1	52
106	Do Migrants Overreport Adherence to Highly Active Antiretroviral Therapy?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 646-647.	2.1	9
107	Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 2127-2131.	2.2	37
108	Integrating HIV-specific elements in the treatment of tobacco dependence. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0